Outcomes of Tocilizumab for Cytokine Release Syndrome After Post-Transplant Cyclophosphamide [0.03%]
托珠单抗对环磷酰胺后移植物细胞因子释放综合征的疗效
Tuan L Phan,Roberta Azbell,Hannah Choe et al.
Tuan L Phan et al.
Background: Cytokine release syndrome (CRS) is common after allogeneic hematopoietic cell transplantation (alloHCT) using post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis. Although tocilizumab effectively ma...
CAR-T CELLS FATE AFTER INFUSION: CELLULAR KINETICS AND MOLECULAR MONITORING [0.03%]
CAR-T细胞回输后的命运：细胞动力学和分子监测
Luisa Anelli,Cosimo Cumbo,Angela Minervini et al.
Luisa Anelli et al.
Chimeric antigen receptor (CAR) T cells are considered human gene therapy products in which T lymphocytes are genetically modified to recognize a specific target antigen for therapeutic purposes. CAR-T cell therapy has shown particular succ...
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell Lymphoma [0.03%]
比较氟达拉滨与苯达莫司汀作为大B细胞淋巴瘤CAR-T回输前预处理化疗的疗效及安全性：一项随机、开放、平行对照的单中心临床研究
Nausheen Ahmed,Alaa Ali,Soyoung Kim et al.
Nausheen Ahmed et al.
Background: Lymphodepleting chemotherapy (LD) enhances chimeric antigen receptor T cell (CAR-T) expansion, persistence, and clinical activity. Fludarabine-cyclophosphamide is most used, but the benefit of alternative agen...
Absence of pretransplant peripheral blasts is a favorable factor in allogeneic stem cell transplantation for advanced acute lymphoblastic leukemia [0.03%]
allo-HSCT前外周血无白血病细胞的成人Ph阴性淋巴细胞白血病患者预后良好
Hiroyasu Ogawa,Katsuji Kaida,Takayuki Inoue et al.
Hiroyasu Ogawa et al.
To clarify the effects of leukemic burden on the outcome of patients with acute lymphoblastic leukemia (ALL) undergoing allo-SCT in non-CR, we retrospectively analyzed data from 377 patients with ALL who underwent one of 4 allo-SCTs: relate...
Haploidentical versus HLA-Matched Unrelated Donors for Hematopoietic Cell Transplantation in Acute Leukemia: A Multicenter Observational Study in a Developing Country Facilitated by Collaboration between the CIBMTR and the Brazilian Society of Cellular Therapy and Bone Marrow Transplantation (SBTMO) [0.03%]
基于CIBMTR与巴西骨髓移植和细胞治疗学会（SBTMO）合作的多中心观察研究：急性白血病患者供者选择造血干细胞移植的半相合与无关全合供者的比较研究
Mariana Nassif Kerbauy,Leonardo Javier Arcuri,Vergilio Antonio Rensi Colturato et al.
Mariana Nassif Kerbauy et al.
Reduced Toxicity Conditioning Allogeneic Hematopoietic Cell Transplantation with Once Daily Intravenous Busulfan for Relapsed/Refractory Lymphoma - a Phase II Study [0.03%]
低毒力预处理allo-HCT联合口服苯达莫司汀治疗复发/难治淋巴瘤的研究——一项II期临床试验
Carl Shultz,Shreyas Shirodkar,Chelby Wakefield et al.
Carl Shultz et al.
Association of a Digital Clinical Decision Support Platform With Early Outcomes After Pediatric Allogeneic Hematopoietic Cell Transplantation: A Three-Era Guideline Implementation Cohort Study [0.03%]
一种数字临床决策支持平台在儿科同种异体造血细胞移植后早期结局中的关联：一项三阶段指南实施队列研究
Kanayo Collins Nwankwo,Elizabeth Klein,Eric Leroux et al.
Kanayo Collins Nwankwo et al.
Background: Practice variation in supportive care contributes to potentially preventable morbidity after pediatric allogeneic hematopoietic cell transplantation (HCT). Digital clinical decision-support platforms may impro...
Cytomegalovirus After Autologous Hematopoietic Cell Transplantation: Impact on Outcome and A Personalized Risk-adapted Prevention Strategy [0.03%]
自身造血细胞移植后巨细胞病毒感染：对预后的影响及个性化预防策略
Alicja Sadowska-Klasa,Hu Xie,Leona A Holmberg et al.
Alicja Sadowska-Klasa et al.
Background: Autologous hematopoietic cell transplantation (auto-HCT) is standard consolidation therapy, but the incidence and impact of cytomegalovirus (CMV) infection post-auto-HCT remain poorly defined. Current guidelin...
Exercise Prehabilitation for Older Adults Undergoing CAR-T: Feasibility, Acceptability, and Preliminary Outcomes [0.03%]
老年人接受CAR-T治疗的运动预康复：可行性、可接受性和初步结果
Nathan H Parker,Jongphil Kim,Morgan Bean et al.
Nathan H Parker et al.
None. Keywords: CAR-T; exercise; functional performance; older adults; prehabilitation. ...
Trends and Disparities in CAR-T Therapy Utilization, Inpatient Mortality, Length of Stay, and Costs in the United States (2017-2022) [0.03%]
美国CAR-T治疗利用、住院死亡率、住院时间和费用的趋势和差异（2017-2022年）
Simo Du,Jiahao Peng,Tiantian Zhang et al.
Simo Du et al.
Background: Since FDA approval in August 2017, chimeric antigen receptor T-cell (CAR-T) therapy has rapidly transformed the treatment landscape of relapsed or refractory hematologic malignancies. However, national data de...